DALLAS--(BUSINESS WIRE)--Lantern Pharma Inc., is a clinical stage biotech company pioneering the field of precision oncology driven by advanced genomics and machine learning-based artificial intelligence (AI) techniques. Lantern today announced that will present at the 9th Annual Biotech Showcase™ on Wednesday, January 11, 2017 at the Hilton San Francisco Union Square. Taking place during one of the industry’s largest annual healthcare investor conferences, this conference attracts investors and pharmaceutical executives from around the world focused on investment and business, partnership development opportunities in the bio-tech industry.
Lantern will present on Wednesday, January 11, 2017 at 2:45 p.m. PST, in Room 1 (Ballroom Level). Arun Asaithambi, Ph.D., Chief Executive Officer, will provide an overview of the company, including its precision-oncology programs.
About Lantern Pharma Inc
Lantern Pharma is a clinical stage biotech company is aiming to re-invent the cancer drug development process by tailoring promising drug programs to the right cancer patients through biomarker discovery. Lantern leverages advanced genomics and machine learning based artificial intelligence (AI) techniques to both identify and significantly reduce the cost and overall risk profile of new therapies compared to traditional drug development. Lantern currently has three clinical stage candidates in its pipeline. LP-300(Tavocept) is a phase 2 clinical candidate. LP-184 is being prepared for biomarker based clinical trials. Irofulven-1 has been licensed out to a later stage pharma company focused on continuing its development.